Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Amosulalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 13/20 | 0.96 |
| ▸ | DRD2 | P14416 | 6/20 | 0.96 |
| ▸ | DRD3 | P35462 | 6/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.96 |
| ▸ | HTR1A | P08908 | 4/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.96 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.96 |
| ▸ | DRD1 | P21728 | 4/20 | 0.64 |
| ▸ | DRD4 | P21917 | 4/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amosulalol SCHEMBL6509394 | 0.98 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL30136493 | 0.98 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL48933 | 0.98 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL11020103 | 0.97 | ADRB2 (0.98) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL50631 | 0.97 | ADRB2 (0.98) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| SCHEMBL11473050 | 0.90 | ADRB2 (0.85) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| SCHEMBL11471245 | 0.90 | ADRB2 (0.85) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Hydrochloric Acid SCHEMBL11472523 | 0.89 | ADRB2 (0.83) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| SCHEMBL11471087 | 0.89 | ADRB2 (0.83) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Hydrochloric Acid SCHEMBL11400227 | 0.89 | ADRB2 (0.83) | ADRB2DRD2DRD3ADRB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1303306-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885DRD2 1310/4885DRD3 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.